

**Musculoskeletal Australia
Pharmaceutical Benefits Advisory Committee (PBAC)**



MUSCULOSKELETAL
AUSTRALIA

Musculoskeletal relevant drugs considered at the March 2021 PBAC Meeting

Below is a list of the musculoskeletal relevant drugs that were considered by the PBAC at their meeting in March 2021. The decision of the PBAC regarding each of these drugs is provided in the right column of the table below.

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	Decision of the PBAC regarding these drugs at the March 2021 meeting
<p>FILGOTINIB (this had been listed for the November 2020 meeting of PBAC, but was withdrawn prior to the meeting)</p>	<p>Rheumatoid arthritis (RA)</p>	<p>Gilead Sciences Pty Ltd requested that this drug be approved in tablet form (two different strengths) for the treatment of severe active rheumatoid arthritis. The brand name is Jyseleca®</p>	<p>The submission was withdrawn.</p>

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	Decision of the PBAC regarding these drugs at the March 2021 meeting
TERIPARATIDE	Severe established osteoporosis	Gedeon Richter Australia Pty Ltd submitted a minor submission requesting a change to the listing of Teriparatide so it is listed under the same conditions as its reference biologic. The brand name is Terrosa.	<p>The PBAC recommended the listing of the biosimilar brand of teriparatide (Terrosa) as an Authority Required (STREAMLINED) listing for the same indications as the reference brand Forteo.</p> <p>The PBAC recommended listing Terrosa on a cost minimisation basis to Forteo. The PBAC advised that, under Section 101(4AACD) of the <i>National Health Act 1953</i>, in the Schedule of Pharmaceutical Benefits, Terrosa and Forteo should be treated as equivalent ('a' flagged) to each other. The PBAC recommended the addition of an administrative note to encourage the uptake of biosimilar prescribing for treatment naïve patients, in accordance with the Australian Government's Biosimilar Uptake Driver policy.</p>
UPADACITINIB	Ankylosing spondylitis (AS)	Abbvie Pty Ltd requested a change to the listing of Upadacitinib so that it is available in tablet form (15mg) for the treatment of AS. The brand name is Rinvoq®	<p>The PBAC recommended the Authority Required listing of upadacitinib for the treatment of AS.</p> <p>The PBAC's recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of upadacitinib would be acceptable if it were cost minimised to the lowest cost biologic disease modifying anti-rheumatic drug (bDMARD) for this indication.</p>

Drug name	Musculoskeletal condition/s (What is the drug used to treat?)	Purpose of the submission (Nature of the request by the sponsor or drug company)	Decision of the PBAC regarding these drugs at the March 2021 meeting
UPADACITINIB	Psoriatic arthritis	Abbvie Pty Ltd requested a change to the listing of Upadacitinib so that it is available in tablet form (15mg) for the treatment of psoriatic arthritis. The brand name is Rinvoq®	<p>The PBAC recommended the Authority Required listing of upadacitinib for the treatment of PsA.</p> <p>The PBAC’s recommendation for listing was based on, among other matters, its assessment that the cost-effectiveness of upadacitinib would be acceptable if it were cost minimised to the lowest cost biologic disease modifying anti-rheumatic drug (bDMARD) for this indication.</p>